Biofrontera : Notice of half-year report of 2016

Biofrontera AG

Notice of half-year report of 2016

Leverkusen, Germany, 25 August 2016 - Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, will be announcing its financial results for the six- month period ended June 30, 2016 on 31 August 2016.

Conference calls for shareholders and interested investors will be held on 31 August 2016 at the following times:

Dial-in number: +49-(0)69 271340800

Conference code: 96247638#

Dial-in number Germany: +49-(0)69 271340800

Dial-in number UK: +44 203 36 45 807

Dial-in number USA: +1 240 64 50 345

Dial-in number USA (New York): +1 646 66 37 901

Conference code: 31292670#

Ends

Enquiries, please contact:

Background:

Biofrontera Group (FSE: B8F, ISIN DE0006046113) Biofrontera is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which was initially approved and marketed in Europe and is now also approved in the US for the treatment of mild and moderate actinic keratosis, a precursor to squamous cell carcinoma, with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralized EU and now US approval for a medical device/drug it has developed itself.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel, a scalp tonic and acute roll-on, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

For more information, visit www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.